Louis Chrystal has filed 3 insider transactions across 1 company since May 2024.
Most recent transaction: a grant/award of 420000 shares of TScan Therapeutics, Inc. ($TCRX) on January 20, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 20, 2026 | TScan Therapeutics, Inc. | $TCRX | Louis Chrystal | Chief Medical Officer | A | Stock Option (Right to Buy) | 420000 | $0.00 | 420,000.0000 | 129,835,938 | 9999.99% | 0.32% |
| Jan. 3, 2025 | TScan Therapeutics, Inc. | $TCRX | Louis Chrystal | Chief Medical Officer | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 111,990,417 | 9999.99% | 0.36% |
| May 1, 2024 | TScan Therapeutics, Inc. | $TCRX | Louis Chrystal | Chief Medical Officer | A | Stock Option (Right to Buy) | 380000 | $0.00 | 380,000.0000 | 65,599,858 | 9999.99% | 0.58% |